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testinal BD shows a fluctuating clinical course with repeated 
episodes of relapses and remissions.7,8 Gastrointestinal in-
volvement of BD, often related to poor treatment responses 
and catastrophic bowel complications, can be life-threaten-
ing in some cases,9,10 although symptoms of intestinal BD 
range from mild abdominal discomfort to massive bleeding, 
fistula, or bowel perforation.6,7 Indeed, intestinal BD requires 
similar surgical interventions to those of CD, predicting a 
poor prognosis.11 However, clinical data regarding the diag-
nosis of intestinal BD and predicting factors for its disease 
activity and long-term outcomes are still limited because of 
INTRODUCTION
Behçet’s disease (BD) is a multisystemic, chronic, relaps-
ing systemic inflammatory disorder characterized mainly by 
oral and genital ulcers, uveitis, skin manifestations, and joint, 
vascular, CNS, and gastrointestinal involvements.1-3 When 
patients with BD present with predominant gastrointestinal 
symptoms and intestinal ulcerations observed objectively, 
they may be diagnosed with intestinal BD.4,5 The prevalence 
of intestinal BD is higher in East Asia, including Korea and 
Japan, than in Mediterranean countries.6 Similar to IBD, in-
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Intestinal Behçet’s disease (BD), generally accepted as a type of inflammatory bowel disease (IBD), could be diagnosed when 
patients with BD have objectively documented gastrointestinal symptoms and intestinal ulcerations. Similar to IBD, intestinal 
BD has an unpredictable disease course with relapse and remission and is often related to a poor prognosis. However, there is 
no single gold standard for assessment of the disease activity of intestinal BD, and its diagnosis and management depend heav-
ily on expert opinions. The Korean IBD Study Group recently developed novel diagnostic criteria based on colonoscopy find-
ings and clinical manifestations using a modified Delphi process to overcome drawbacks of previously used consensus for the 
diagnosis of intestinal BD. In addition, the recently developed disease activity index for intestinal BD, consisting of a relatively 
simple 8-point index, could also help in determining treatment strategies and monitoring therapeutic responses. In this review, 
the progress in the diagnosis and disease activity measurement of intestinal BD will be discussed. (Intest Res 2017;15:311-317)
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its scarcity. The Korean IBD Study Group recently proposed 
novel diagnostic criteria and an index to assess the disease 
activity of intestinal BD. Here, we will review the progress in 
the diagnosis and assessment of the disease activity of intes-
tinal BD.
DIAGNOSIS OF INTESTINAL BD
The incidence of gastrointestinal involvement in BD 
shows a remarkable geographic variation, ranging from 0% 
to 60%, which seems to be more prevalent in East Asia.6,12 
Although the gastrointestinal involvement of BD may be re-
lated to a poor prognosis in affected patients, to date, no spe-
cific diagnostic criteria have been developed for intestinal 
BD because of its rareness and lack of clinical evidence. 
Intestinal BD is generally diagnosed if patients have both 
intestinal ulcerations and clinical findings of systemic BD. 
Diagnosis should be made considering the clinical, endo-
scopic, radiologic, and pathologic findings.13,14 The clinical 
manifestations need to meet the diagnostic criteria of BD as 
suggested by the International Study Group for BD or the BD 
Research Committee of Japan.15,16 The common gastrointes-
tinal symptoms include abdominal pain, diarrhea, bleeding, 
and weight loss, and the typical intestinal ulcerations are 
defined as <5 ulcers that are oval in shape and deep with dis-
crete borders located in the ileocecal area (Fig. 1).17 Howev-
er, various ulcerations could be observed from aphthous ul-
cers to deep and penetrating volcano-shaped ulcers, and not 
only focal distribution but also diffuse ulcerations present in 
patients with intestinal BD.18 The representative pathologic 
findings of intestinal BD include the presence of vasculitis 
involving small- and medium-sized vessels and lymphocyte 
infiltration in the perivascular space.19,20 The absence of a 
noncaseating granuloma would indicate intestinal BD rather 
than CD, although such a finding is identified in less than 
half of the CD cases. 
1. Differential Diagnosis
Other diseases that mimic intestinal BD should be ruled 
out before intestinal BD is diagnosed, including tubercu-
losis, CD, nonspecific colitis, and drug-associated colitis.21 
Intestinal BD and CD indeed share numerous similarities, 
such as nonspecific gastrointestinal symptoms, extraintes-
tinal manifestations, wax-and-wane disease courses, and 
long-term clinical outcomes; thus, it is sometimes difficult 
to distinguish between the 2.7,11 However, clinically, oral and 
genital ulcerations are more common in intestinal BD, while 
Fig. 1. Colonoscopic findings of intestinal 
Behçet’s disease. (A, B) Typical ulcers for 
intestinal Behçet’s disease are defined as 
single or few deep oval-shaped ulcers with 
discrete margins in the ileocecal area. (C, 
D) Atypical ulcers for intestinal Behçet’s 
disease are defined as intestinal ulcerations 
that do not meet all of these characteris-
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perianal lesions, stricture, and fistula formations are more 
frequent in CD.11,22 Endoscopically, longitudinal ulcers with 
a cobblestone appearance are frequently observed in CD, 
whereas intestinal lesions in intestinal BD tend to appear as 
few round-shaped, punched-out, deep ulcers with discrete 
margins, which are more prone to perforate.17 Lee et al.23 
suggested simplified algorithms for the differential diagnosis 
of the 2 disease entities by investigating their colonoscopic 
features. Five colonoscopy findings, including a round ulcer 
shape, focal distribution, fewer than 6 ulcers, absence of aph-
thous lesions, and cobblestone appearance were indepen-
dently dominant in intestinal BD, and by sequentially apply-
ing 2 variables with ulcer shape followed by distribution, the 
2 diseases could be differentiated up to 92%.
Intestinal tuberculosis (ITB) may also be difficult to dis-
tinguish from intestinal BD and CD because of its overlap in 
endoscopic appearance and prevalent geographic regions. 
According to a study by Lee et al.,24 involvement of fewer 
than 4 segments, patulous ileocecal valves, transverse ulcers, 
and scars or pseudopolyps were observed commonly in ITB, 
and anorectal lesions, longitudinal ulcers, aphthous ulcers, 
and cobblestone appearance were seen frequently in CD. 
Using these colonoscopic parameters, ITB can be diagnosed 
correctly in 87.5% of the patients. 
2. Novel Diagnostic Criteria for Intestinal BD
According to the Japanese consensus-based practice 
guidelines for the diagnosis of intestinal BD using a modified 
Delphi approach, patients should have both confirmed BD 
and intestinal lesions without other gastrointestinal diseases 
to enable a definite diagnosis of intestinal BD.21 Some pa-
tients with typical intestinal ulcers do not meet the diagnos-
tic criteria of BD, and systemic manifestations may appear 
sequentially after several months or years after initial intesti-
nal ulcerations in others.17,25,26 One of the major concerns of 
the Japanese diagnostic criteria includes intestinal involve-
ments in patients without clinical findings of BD. Lee et al.17 
reported that the clinical and colonoscopic characteristics of 
patients with intestinal involvement who lack the systemic 
manifestations of BD were in accordance with the character-
istics of those who fulfill the criteria. Shin et al.26 also showed 
that patients who have typical ulcerations without systemic 
BD symptoms tended to satisfy the BD criteria throughout 
the disease course. Another concern is that the characteris-
tics of intestinal lesions are difficult to define. Simple intes-
tinal ulcers are often considered as a variation of the same 
disease spectrum of intestinal BD because intestinal lesions 
initially presenting as simple ulcers could be eventually diag-
nosed as intestinal BD over time.27,28 Therefore, to date, clini-
cians are apt to diagnose and manage intestinal BD even in 
patients who do not fully satisfy the systemic manifestation 
criteria for BD at the time of colonoscopy. 
Owing to these unmet needs, the Korean IBD Study Group 
recently developed novel diagnostic criteria for intestinal 
BD.29 These diagnostic criteria were developed on the basis 
of the colonoscopic findings and extraintestinal systemic 
manifestations using a modified Delphi method. The ex-
traintestinal manifestations were classified in accordance 
with the diagnostic criteria by the BD Research Committee 
of Japan16 that can reflect a temporal change better than the 
International Study Group for BD criteria during follow-
up. The newly developed criteria categorized patients into 
4 groups: definite, probable, suspected, and nondiagnostic 
(Fig. 2) and suggested a management strategy according to 
each category. Patients with typical intestinal ulcerations 
and extraintestinal symptoms who met the Japanese criteria 
were categorized as the “definite” intestinal BD group and 
managed for intestinal BD. Patients with typical intestinal ul-
cerations with only typical oral symptoms or atypical intes-
tinal ulcerations and extraintestinal symptoms who met the 
Japanese criteria were categorized as the “probable” group. 
Patients with typical intestinal ulcerations without any ex-
traintestinal symptoms or atypical intestinal ulcerations with 
Patients with ulcer in ileocecal area
Typical intestinal ulcer Atypical intestinal ulcer
Oral ulcer only NoneSystemic BD
a
Oral ulcer only NoneSystemic BD
a





Fig. 2. Algorithm for the diagnosis of 
intestinal Behçet’s disease (BD) based on 
the type of ileocolonic ulcerations and 
clinical manifestations. aThe subtypes of 
systemic BD (complete, incomplete, and 
suspected) were classified in accordance 
with the diagnostic criteria of the Research 
Committee of Japan; bA close follow-up is 
necessary. Adapted from Cheon JH, et al.29 
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only typical oral symptoms were categorized as the “sus-
pected” group. Patients in the probable or suspected group 
needed to be followed up closely because a substantial 
number of patients are eventually diagnosed with intestinal 
BD. The “nondiagnostic” group included patients who had 
only atypical intestinal ulcerations without any extraintes-
tinal manifestations. These newly developed algorithms for 
the diagnosis of intestinal BD might be useful, especially in 
patients with intestinal ulcerations in the ileocecal area who 
do not fully satisfy the diagnostic criteria of systemic BD.
DISEASE ACTIVITY MONITORING OF 
INTESTINAL BD
Intestinal BD showed a heterogeneous range of clinical 
courses over time. In a retrospective study by Jung et al.30 an-
alyzing the clinical course of patients with intestinal BD who 
were regularly followed up for at least 5 years, majority of 
the patients (71.6%) had a mild clinical activity, whereas the 
remaining patients (28.4%) had multiple relapses or chronic 
symptoms. In addition, intestinal BD often requires surgery 
because of complications, including massive bleeding, fis-
tula formation, and perforation.7,9 The cumulative rates of 
surgery were reported to be 31.6% at 5 years and 44.4% at 
10 years after diagnosis, which were comparable to those of 
CD.11 Even after surgery, the cumulative clinical recurrence 
rates were shown to be 21.1% at 1 year and 51.1% at 5 years.11 
Considering its unpredictable disease flare-ups and poor 
overall prognosis, the objective assessment of its disease 
activity is indispensable in determining the best therapeutic 
strategy and in assessing the treatment response.
1. Endoscopy
Endoscopy plays an essential role in the measurement of 
the disease extent and severity of IBD.31 Kim et al.18 analyzed 
the clinical outcomes of patients with intestinal BD accord-
ing to the colonoscopy findings that volcano-type ulcer-
ations were prone to show less favorable responses to medi-
cations, more frequent surgical intervention, and recurrence 
than the aphthous and geographic ulcerations. Lee et al.32 
also suggested that more than 2 ulcers and volcano-shaped 
ulcers were associated with higher disease activities. 
As mucosal healing has emerged as a treatment target 
in IBD, the need for endoscopy continues to increase.33,34 
In agreement with previous studies in IBD,35,36 Yim et al.37 
reported that mucosal healing was an independent factor 
for favorable clinical outcomes with a lower recurrence rate 
in patients with intestinal BD. The presence of active ulcer-
ations was associated with a higher risk of disease relapse 
even in clinical remission status, which might implicate the 
role of mucosal healing as a therapeutic target in the man-
agement of intestinal BD. 
In addition, endoscopy is considered the gold standard in 
the diagnosis of postoperative recurrence and prediction of 
clinical outcomes in IBD. The postoperative Crohn’s endo-
scopic recurrence study revealed that early colonoscopy and 
step-up treatment are better than conventional drug therapy 
alone for the prevention of postoperative CD recurrence.38 
Recently, our group developed an endoscopic scoring sys-
tem predicting clinical relapse after surgery in patients with 
intestinal BD using colonoscopic findings, including ulcer 
size and numbers. Multiple and >20 mm-sized ulcers were 
related to clinical relapse after surgery in patients with intes-
tinal BD (data unpublished). However, while widely accept-
ed to represent the state of bowel inflammation, endoscopy 
still has limitations of cost, inconvenience, and invasiveness.
2. Biomarkers
To complement these drawbacks, various biomarkers have 
been studied to estimate the severity of inflammation and 
monitor the disease activities. Among laboratory markers, 
ESR and CRP are the most studied and considered the most 
representative.39,40 ESR and CRP levels were well correlated 
with the disease activity of systemic BD,41,42 and a higher CRP 
level was proven to be a predictor of relapse in patients with 
intestinal BD with 5-aminosalicylic acid/sulfasalazine treat-
ment.43 In addition, cumulative recurrence rates and reop-
eration rates were higher in surgically treated patients with 
higher CRP levels than in those with lower CRP.44 
Choi et al.45 found that the positive rate of anti-Saccharomy-
ces cerevisiae antibodies was 44.3% in patients with intestinal 
BD; anti-S. cerevisiae antibody positivity was significantly as-
sociated with increased surgical rates. In addition, Shin et al.46 
reported that the prevalence of anti-α-enolase antibody was 
67.5% in patients with intestinal BD, and a cumulative steroid 
use was higher in patients with a positive anti-α-enolase 
antibody than in those with a negative antibody. Recently, 
serum soluble triggering receptor expressed on myeloid 
cells-1, which is known to play a role in the inflammatory 
response by stimulating the productions of proinflamma-
tory cytokines,47 has been shown to increase in patients with 
intestinal BD; further, its levels showed a higher correlation 
with the disease activity of intestinal BD than CRP and ESR 
levels.48 In addition, a recent study found that levels of IL-12B 
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involved in Th17 differentiation were significantly correlated 
with clinical and endoscopic activities of intestinal BD impli-
cating its potential role as a biomarker.49 On the other hand, 
procalcitonin was able to differentiate infection from active 
inflammation in IBD in that it was not affected by the disease 
activity of intestinal BD but by a concomitant infection.50
Compared to serologic biomarkers, fecal biomarkers, such 
as calprotectin and lactoferrin, have the advantage in terms 
of increased specificity for intestinal inflammation.40,51 Kim et 
al.52 suggested that similar to IBD, levels of fecal calprotectin 
were significantly higher in patients with typical ulcerations 
than in those with atypical ulcerations, and the absolute 
changes in fecal calprotectin and disease activity index for 
intestinal BD (DAIBD) showed a significant correlation dur-
ing 3 months of treatment. However, to date, no single bio-
marker has been proven to be ideal in assessing the disease 
activity of intestinal IBD.
3. Disease Activity Index for Intestinal BD
To date, there is no specific tool to assess the disease activ-
ity of intestinal BD; therefore, the measurement of its dis-
ease activity depends heavily on expert opinions or the use 
of other IBD indices, such as the CDAI.21 The Korean IBD 
Study Group accordingly developed a novel tool to measure 
the disease activity of intestinal BD.53 As a single clinical or 
laboratory parameter could not consistently reflect the level 
of intestinal inflammation, a multi-item measurement simi-
lar to CDAI54 and pediatric ulcerative colitis activity index55 
was needed to evaluate the disease activity of intestinal BD. 
DAIBD consists of 8 items as follows: general well-being, fe-
ver, extraintestinal manifestations, abdominal pain, abdomi-
nal mass, abdominal tenderness, intestinal complication, 
and number of liquid stools (Table 1), ranging from a score 
of 0 to 325. Depending on the DAIBD score, the disease se-
verity was divided into 4 groups (Table 2): quiescent (≤19), 
mild (20–39), moderate (40–74), and severe (≥75) diseases. 
DAIBD showed a better performance than CDAI in terms 
of good correlation with the physician’s global assessment. 
DAIBD has also advantages over CDAI as it is a relatively 
simple 8-point index and is easily applied in the outpatient 
clinic. However, the recent study failed to show the correla-
tion between DAIBD and endoscopic severity, similar to 
CD.32,56 Meanwhile, a multinational web-based survey re-
ported that even in Asian countries, physicians adopted dif-
Table 1. Disease Activity Index for Intestinal Behçet’s Disease 
Item Score
General well-being for 1 week
   Well  0
   Fair 10
   Poor 20
   Very poor 30
   Terrible 40
Fever (°C)
   <38  0
   ≥38 10
Extraintestinal manifestationsa 5 Per item
Abdominal pain in 1 week
   None  0
   Mild 20
   Moderate 40
   Severe 80
Abdominal mass
   None  0
   Palpable mass 10
Abdominal tenderness
   None  0
   Mildly tender 10
   Moderately or severely tender 20
Intestinal complicationsb 10 Per item
No. of liquid stools in 1 week
   0  0
   1–7 10
   8–21 20
   22–35 30
   ≥36 40
aScore 5 for oral ulcer, genital ulcer, eye lesion, skin lesion, or arthralgia; 
score 15 for vascular involvement or CNS involvement.
bFistula, perforation, abscess, or intestinal obstruction.
Adapted from Cheon JH, et al. Inflamm Bowel Dis 2011;17:605-613.53
Table 2. Cutoff Scores of the Disease Activity Index for Intestinal 
Behçet’s Disease





DAIBD, disease activity index for intestinal Behçet’s disease.
Adapted from Cheon JH, et al. Inflamm Bowel Dis 2011;17:605-613.53
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ferent scoring systems to assess the disease activity of IBD.57 
Further studies are mandatory to validate the usefulness of 
DAIBD in various populations and predict the clinical out-
comes more precisely by considering both endoscopic fac-
tors and clinical activity indices.
CONCLUSIONS
Gastrointestinal involvement is one of the major causes 
of morbidity and mortality in BD. However, clinical data are 
limited because of the scarcity of intestinal BD cases, and 
to date, there has been no standardized diagnostic tool or 
pathognomonic finding for intestinal BD. Recently devel-
oped novel diagnostic criteria and a disease activity index 
might help physicians make a correct diagnosis and decide 
an appropriate treatment by assessing the disease activity 
of intestinal BD. Further international validation for these 
guidelines is needed, and biomarkers specific for intestinal 
BD in the diagnosis, disease activity assessment, and clinical 
outcome prediction should be investigated in the future.
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